Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03150511 · ClinicalTrials.gov registry record · Phase 2
Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury
A Phase 2 study of Peripheral Nerve Injuries, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT03150511: Recruiting Phase 2 study of Peripheral Nerve Injuries, sponsored by Johns Hopkins University.
NCT03150511 is a Phase 2 study of Peripheral Nerve Injuries that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 36 participants, below the 457-participant average among 8 other Peripheral Nerve Injuries trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03150511, a Phase 2 study of Peripheral Nerve Injuries, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries. The investigators hypothesize that treatment with tesamorelin will result in faster and more substantial recovery of motor and sensory function following surgical repair of injured peripheral nerves. Patients with upper extremity nerve injuries will be randomly assigned to receive either tesamorelin treatment or no treatment. Assessments for nerve regeneration, muscle function, and sensation will be conducted every three months for a total of 12 months. Outcomes in patients receiving tesamorelin will be compared to those in the untreated group to determine the effectiveness of tesamorelin as a therapeutic intervention for nerve injuries.
Primary Outcome
Pinch strength measure as measured by a pinch gauge.
Conditions Studied
Interventions
- DRUG Tesamorelin 2 Milligrams (MG)
Study Locations (1)
Maryland
- Sami Tuffaha - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT03150511 shows while recruiting
NCT03150511 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 457-participant average among 8 other Peripheral Nerve Injuries trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Peripheral Nerve Injuries appearing as the primary indexed condition, and to 1 intervention - of which Tesamorelin 2 Milligrams (MG) is the first listed.
NCT03150511 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT03150511 about?
NCT03150511 is a clinical study titled "Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury". The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries. The investigators hypothesize that treatment with tesamorelin will result in faster and more substantial recovery of motor and sensory function following surgical repair of injured p...
What is the current status of trial NCT03150511?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2018-06-01. Estimated completion is 2027-12.
What conditions does trial NCT03150511 study?
This clinical trial studies the following conditions: Peripheral Nerve Injuries.
What interventions are being tested in trial NCT03150511?
The interventions under investigation include: Tesamorelin 2 Milligrams (MG) (DRUG).
Who is sponsoring clinical trial NCT03150511?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03150511 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Nerve Injuries
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03150511's enrollment target sits among peer trials
36 9th of 8 the lowest of 8 other Peripheral Nerve Injuries trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Nerve Injuries trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)
RECRUITING · Phase 2
-
Safety and Efficacy of NTX-001 Compared to SOC in Acute Single Peripheral Nerve Injuries
COMPLETED · Phase 2
-
Harnessing Neuroplasticity to Enhance Functional Recovery During Chronic Recovery From Upper Extremity Nerve Repair
RECRUITING · NA
-
Promoting Healing of Injured Nerves With Electrical Stimulation Therapy
RECRUITING · NA
-
Upper Extremity Functional Electrical Stimulation (FES) for Restoration of Upper Extremity Function After Spinal Cord Injury (SCI)
RECRUITING · NA
-
A Comparison of NeuroSpan Bridge, NeuraGen Nerve Guide, and Nerve Autograft for Peripheral Nerve Repair
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI